Clinical Research Directory
Browse clinical research sites, groups, and studies.
AZA+Lus VS AZA Monotherapy in HR-MDS
Sponsor: Peking Union Medical College Hospital
Summary
This study is a randomized, prospective, single-center, open-label cohort study involving untreated HR-MDS patients. The patients were divided randomized into AZA+Lus cohort and AZA monotherapy cohort.
Official title: Azacitidine Plus Luspatercept Versus Azacitidine Monotherapy in Higher-risk Myelodysplastic Neoplasms: a Randomized Prospective Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
86
Start Date
2025-04
Completion Date
2027-01-31
Last Updated
2025-04-15
Healthy Volunteers
No
Conditions
Interventions
Azacitidine (AZA)
Azacitidine 75mg/m/ day \*5 days, 28 days for 1 course
Luspatercept
Luspatercept 1.0 mg/kg subcutaneously every 3 weeks, adjusted according to hemoglobin, up to 1.75mg/kg. If hemoglobin ≥120g/L, luspatercept can be discontinued.